![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: F3 |
Gene summary for F3 |
![]() |
Gene information | Species | Human | Gene symbol | F3 | Gene ID | 2152 |
Gene name | coagulation factor III, tissue factor | |
Gene Alias | CD142 | |
Cytomap | 1p21.3 | |
Gene Type | protein-coding | GO ID | GO:0001525 | UniProtAcc | P13726 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2152 | F3 | CA_HPV_2 | Human | Cervix | CC | 2.21e-04 | 3.30e-01 | 0.0391 |
2152 | F3 | CCI_1 | Human | Cervix | CC | 4.25e-04 | 7.51e-01 | 0.528 |
2152 | F3 | Tumor | Human | Cervix | CC | 2.51e-08 | 3.34e-01 | 0.1241 |
2152 | F3 | sample3 | Human | Cervix | CC | 1.32e-32 | 7.49e-01 | 0.1387 |
2152 | F3 | H2 | Human | Cervix | HSIL_HPV | 5.58e-23 | 6.21e-01 | 0.0632 |
2152 | F3 | L1 | Human | Cervix | CC | 4.16e-03 | 3.84e-01 | 0.0802 |
2152 | F3 | T1 | Human | Cervix | CC | 3.80e-04 | 2.82e-01 | 0.0918 |
2152 | F3 | T2 | Human | Cervix | CC | 4.70e-03 | 3.29e-01 | 0.0709 |
2152 | F3 | T3 | Human | Cervix | CC | 3.43e-27 | 7.34e-01 | 0.1389 |
2152 | F3 | LZE4T | Human | Esophagus | ESCC | 4.67e-04 | -1.98e-01 | 0.0811 |
2152 | F3 | LZE8T | Human | Esophagus | ESCC | 3.73e-02 | 2.27e-01 | 0.067 |
2152 | F3 | LZE20T | Human | Esophagus | ESCC | 1.08e-05 | 1.04e+00 | 0.0662 |
2152 | F3 | LZE24T | Human | Esophagus | ESCC | 8.28e-12 | 1.22e+00 | 0.0596 |
2152 | F3 | LZE21T | Human | Esophagus | ESCC | 6.51e-06 | 4.12e-01 | 0.0655 |
2152 | F3 | P5T-E | Human | Esophagus | ESCC | 6.01e-12 | 6.22e-01 | 0.1327 |
2152 | F3 | P8T-E | Human | Esophagus | ESCC | 3.03e-74 | 1.85e+00 | 0.0889 |
2152 | F3 | P9T-E | Human | Esophagus | ESCC | 1.42e-03 | 4.90e-01 | 0.1131 |
2152 | F3 | P10T-E | Human | Esophagus | ESCC | 7.83e-07 | -2.19e-02 | 0.116 |
2152 | F3 | P11T-E | Human | Esophagus | ESCC | 2.87e-07 | 1.55e+00 | 0.1426 |
2152 | F3 | P12T-E | Human | Esophagus | ESCC | 6.72e-55 | 1.65e+00 | 0.1122 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000756517 | Thyroid | ATC | female pregnancy | 82/6293 | 193/18723 | 6.04e-03 | 2.42e-02 | 82 |
GO:004636411 | Thyroid | ATC | monosaccharide biosynthetic process | 39/6293 | 82/18723 | 6.04e-03 | 2.42e-02 | 39 |
GO:199082318 | Thyroid | ATC | response to leukemia inhibitory factor | 44/6293 | 95/18723 | 6.74e-03 | 2.68e-02 | 44 |
GO:000283213 | Thyroid | ATC | negative regulation of response to biotic stimulus | 49/6293 | 108/18723 | 7.19e-03 | 2.84e-02 | 49 |
GO:009030511 | Thyroid | ATC | nucleic acid phosphodiester bond hydrolysis | 107/6293 | 261/18723 | 7.21e-03 | 2.84e-02 | 107 |
GO:004559822 | Thyroid | ATC | regulation of fat cell differentiation | 61/6293 | 139/18723 | 7.28e-03 | 2.86e-02 | 61 |
GO:190225411 | Thyroid | ATC | negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator | 13/6293 | 21/18723 | 7.34e-03 | 2.87e-02 | 13 |
GO:0050678110 | Thyroid | ATC | regulation of epithelial cell proliferation | 151/6293 | 381/18723 | 7.47e-03 | 2.92e-02 | 151 |
GO:00303262 | Thyroid | ATC | embryonic limb morphogenesis | 52/6293 | 116/18723 | 7.67e-03 | 3.00e-02 | 52 |
GO:00351132 | Thyroid | ATC | embryonic appendage morphogenesis | 52/6293 | 116/18723 | 7.67e-03 | 3.00e-02 | 52 |
GO:009951813 | Thyroid | ATC | vesicle cytoskeletal trafficking | 35/6293 | 73/18723 | 7.71e-03 | 3.00e-02 | 35 |
GO:004594811 | Thyroid | ATC | positive regulation of translational initiation | 17/6293 | 30/18723 | 7.88e-03 | 3.06e-02 | 17 |
GO:005105114 | Thyroid | ATC | negative regulation of transport | 183/6293 | 470/18723 | 8.12e-03 | 3.13e-02 | 183 |
GO:00326086 | Thyroid | ATC | interferon-beta production | 28/6293 | 56/18723 | 8.12e-03 | 3.13e-02 | 28 |
GO:00326486 | Thyroid | ATC | regulation of interferon-beta production | 28/6293 | 56/18723 | 8.12e-03 | 3.13e-02 | 28 |
GO:006053814 | Thyroid | ATC | skeletal muscle organ development | 71/6293 | 166/18723 | 8.39e-03 | 3.22e-02 | 71 |
GO:004560023 | Thyroid | ATC | positive regulation of fat cell differentiation | 32/6293 | 66/18723 | 8.63e-03 | 3.28e-02 | 32 |
GO:005070815 | Thyroid | ATC | regulation of protein secretion | 109/6293 | 268/18723 | 8.87e-03 | 3.36e-02 | 109 |
GO:200105632 | Thyroid | ATC | positive regulation of cysteine-type endopeptidase activity | 64/6293 | 148/18723 | 8.98e-03 | 3.39e-02 | 64 |
GO:003953011 | Thyroid | ATC | MDA-5 signaling pathway | 8/6293 | 11/18723 | 9.31e-03 | 3.44e-02 | 8 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa049336 | Cervix | CC | AGE-RAGE signaling pathway in diabetic complications | 25/1267 | 100/8465 | 5.64e-03 | 1.88e-02 | 1.11e-02 | 25 |
hsa0493313 | Cervix | CC | AGE-RAGE signaling pathway in diabetic complications | 25/1267 | 100/8465 | 5.64e-03 | 1.88e-02 | 1.11e-02 | 25 |
hsa0493310 | Esophagus | ESCC | AGE-RAGE signaling pathway in diabetic complications | 72/4205 | 100/8465 | 4.15e-06 | 2.28e-05 | 1.17e-05 | 72 |
hsa0493317 | Esophagus | ESCC | AGE-RAGE signaling pathway in diabetic complications | 72/4205 | 100/8465 | 4.15e-06 | 2.28e-05 | 1.17e-05 | 72 |
hsa049339 | Oral cavity | OSCC | AGE-RAGE signaling pathway in diabetic complications | 69/3704 | 100/8465 | 2.61e-07 | 1.65e-06 | 8.41e-07 | 69 |
hsa0493316 | Oral cavity | OSCC | AGE-RAGE signaling pathway in diabetic complications | 69/3704 | 100/8465 | 2.61e-07 | 1.65e-06 | 8.41e-07 | 69 |
hsa049338 | Prostate | BPH | AGE-RAGE signaling pathway in diabetic complications | 36/1718 | 100/8465 | 1.82e-04 | 1.02e-03 | 6.30e-04 | 36 |
hsa0493315 | Prostate | BPH | AGE-RAGE signaling pathway in diabetic complications | 36/1718 | 100/8465 | 1.82e-04 | 1.02e-03 | 6.30e-04 | 36 |
hsa0493322 | Prostate | Tumor | AGE-RAGE signaling pathway in diabetic complications | 33/1791 | 100/8465 | 3.79e-03 | 1.36e-02 | 8.46e-03 | 33 |
hsa0493332 | Prostate | Tumor | AGE-RAGE signaling pathway in diabetic complications | 33/1791 | 100/8465 | 3.79e-03 | 1.36e-02 | 8.46e-03 | 33 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | Breast | Healthy |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | Cervix | ADJ |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | Cervix | CC |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | Cervix | Healthy |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | Endometrium | EEC |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | Esophagus | ESCC |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | HNSCC | ADJ |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | HNSCC | OSCC |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | HNSCC | Precancer |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | Prostate | BPH |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | Prostate | Healthy |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
F3 | SNV | Missense_Mutation | novel | c.404N>G | p.Tyr135Cys | p.Y135C | P13726 | protein_coding | deleterious(0) | probably_damaging(0.974) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
F3 | SNV | Missense_Mutation | c.521N>A | p.Ser174Asn | p.S174N | P13726 | protein_coding | deleterious(0.02) | possibly_damaging(0.772) | TCGA-AA-3858-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
F3 | SNV | Missense_Mutation | novel | c.127A>G | p.Asn43Asp | p.N43D | P13726 | protein_coding | deleterious(0.04) | possibly_damaging(0.479) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
F3 | SNV | Missense_Mutation | c.529G>T | p.Asp177Tyr | p.D177Y | P13726 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-EI-6513-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
F3 | deletion | In_Frame_Del | c.326_328delCCT | p.Ser109del | p.S109del | P13726 | protein_coding | TCGA-AG-A02N-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | folinic | CR | |||
F3 | SNV | Missense_Mutation | rs187119941 | c.475G>A | p.Val159Ile | p.V159I | P13726 | protein_coding | tolerated(0.33) | benign(0.04) | TCGA-A5-A0R7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
F3 | SNV | Missense_Mutation | c.242N>T | p.Cys81Phe | p.C81F | P13726 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
F3 | SNV | Missense_Mutation | rs759484806 | c.421G>A | p.Gly141Arg | p.G141R | P13726 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
F3 | SNV | Missense_Mutation | novel | c.509A>C | p.Asn170Thr | p.N170T | P13726 | protein_coding | deleterious(0) | benign(0) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
F3 | SNV | Missense_Mutation | novel | c.334G>A | p.Ala112Thr | p.A112T | P13726 | protein_coding | tolerated(0.45) | benign(0.062) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2152 | F3 | DRUGGABLE GENOME, CELL SURFACE | ALT-836 | |||
2152 | F3 | DRUGGABLE GENOME, CELL SURFACE | MORAb-066 | |||
2152 | F3 | DRUGGABLE GENOME, CELL SURFACE | TT-173 | |||
2152 | F3 | DRUGGABLE GENOME, CELL SURFACE | simvastatin | SIMVASTATIN | 19027114 |
Page: 1 |